IP Based Upon Proprietary Processing Methods

Carmell Therapeutics' IP is based on proprietary processing methods of plasticizing proteins that result in a biomaterial that contains biologically active wound healing and regenerative growth factors, and products made from such processing. The Company has an exclusive worldwide license from Carnegie Mellon University on three U.S. patent applications and any derivatives of those. Including these three CMU patents, a total of eight U.S. patents have issued.

The below patent applications have also been converted to filings in Europe, Canada, Japan, Australia, India, and Mexico, and 9 thus far have issued. Carmell is taking an aggressive position with respect to protecting its IP and has other applications in draft.

Issued Patents

U.S. Patent # Title Issued Concepts
8,293,530 Methods and Apparatus for Manufacturing Plasma Based Plastics and Bioplastics Produced Therefrom 10/23/2012 Methods of manufacturing & crosslinking bioplastics from clotted, dried plasma
8,529,956 Methods and Apparatus for Manufacturing Plasma Based Plastics and Bioplastics Produced Therefrom 9/10/2013 Plasticization of blood plasma and products made from clotted, dried plasma
8,529,958 Methods and Apparatus for Manufacturing Plasma Based Plastics and Bioplastics Produced Therefrom 9/10/2013 Powder & Putty products
8,529,959 Methods and Apparatus for Manufacturing Plasma Based Plastics and Bioplastics Produced Therefrom 9/10/2013 Patch & sheet products
8,529,960 Methods and Apparatus for Manufacturing Plasma Based Plastics and Bioplastics Produced Therefrom 9/10/2013 Cartilage and bone products
8,529,961 Methods and Apparatus for Manufacturing Plasma Based Plastics and Bioplastics Produced Therefrom 9/10/2013 Coating products
8,911,789 Methods and Apparatus for Manufacturing Plasma Based Plastics and Bioplastics Produced Therefrom 12/16/2014 Drug delivery
9,364,503 Methods and Apparatus for Manufacturing Plasma Based Plastics and Bioplastics Produced Therefrom 6/14/2016 Drug delivery